0001415889-24-016698.txt : 20240613 0001415889-24-016698.hdr.sgml : 20240613 20240613171020 ACCESSION NUMBER: 0001415889-24-016698 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240611 FILED AS OF DATE: 20240613 DATE AS OF CHANGE: 20240613 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Peyer James CENTRAL INDEX KEY: 0001843594 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39980 FILM NUMBER: 241042114 MAIL ADDRESS: STREET 1: C/O SENSEI BIOTHERAPEUTICS, INC. STREET 2: 1405 RESEARCH BLVD., STE. 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001829802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1405 RESEARCH BLVD, SUITE 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (240) 243-8000 MAIL ADDRESS: STREET 1: 1405 RESEARCH BLVD, SUITE 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 form4-06132024_090616.xml X0508 4 2024-06-11 0001829802 Sensei Biotherapeutics, Inc. SNSE 0001843594 Peyer James 228 PARK AVENUE S. #66643 NEW YORK NY 10003 true false true false 0 Stock Option (Right to Buy) 0.709 2024-06-11 4 A 0 19000 0 A 2034-06-10 Common Stock 19000 19000 I See footnote The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 11, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. These options are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the options, and shares exercisable thereunder, held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such options. /s/ James Peyer 2024-06-13